Literature DB >> 29378033

Cervical Cancer Markers: Epigenetics and microRNAs.

Vishuda Laengsri1,2, Usanee Kerdpin3, Chotiros Plabplueng1,2, Lertyot Treeratanapiboon4, Pornlada Nuchnoi1,2.   

Abstract

Gynecologic malignant neoplasms are a severe health problem among female patients, of which cervical cancer (CC), in particular, is a common disease leading to high mortality rates. Despite extensive attempts by researchers to solve the molecular mystery of CC, the mechanisms of its pathogenesis remain unclear. Tumor markers used in the clinical laboratory, such as squamous cell carcinoma (SCC), cancer antigen (CA)-125, and CA19-9, provide some help in diagnosing patients with CC. However, finding new molecular markers with high sensitivity and specificity is necessary. This review focuses on the role of epigenetic changes, particularly microRNAs (miRNAs), to CC. Several miRNAs that associated with CC potentially have the advantage of being early biomarkers. Moreover, altered serum miRNAs or single nucleotide polymorphisms in miRNA patterns may predict disease progression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29378033     DOI: 10.1093/labmed/lmx080

Source DB:  PubMed          Journal:  Lab Med        ISSN: 0007-5027


  23 in total

1.  Activation of NK cells in male cancer survivors by fucoidan extracted from Cladosiphon okamuranus.

Authors:  Takeaki Nagamine; Kizuku Kadena; Makoto Tomori; Katsuyuki Nakajima; Masahiko Iha
Journal:  Mol Clin Oncol       Date:  2019-10-31

2.  Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer.

Authors:  Woo Yeon Hwang; Dong Hoon Suh; Kidong Kim; Yong Beom Kim; Jae Hong No
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

3.  Exosome-Mediated Transfer of miR-1323 from Cancer-Associated Fibroblasts Confers Radioresistance of C33A Cells by Targeting PABPN1 and Activating Wnt/β-Catenin Signaling Pathway in Cervical Cancer.

Authors:  Fang Fang; Chunfeng Guo; Weinan Zheng; Qin Wang; Limei Zhou
Journal:  Reprod Sci       Date:  2022-03-25       Impact factor: 3.060

4.  PMEPA1 Serves as a Prognostic Biomarker and Correlates with Immune Infiltrates in Cervical Cancer.

Authors:  Jing Li; Wei-Min Kong
Journal:  J Immunol Res       Date:  2022-04-20       Impact factor: 4.493

Review 5.  Human Papillomavirus Infections, Cervical Cancer and MicroRNAs: An Overview and Implications for Public Health.

Authors:  Michela Lucia Sammarco; Manuela Tamburro; Alessandra Pulliero; Alberto Izzotti; Giancarlo Ripabelli
Journal:  Microrna       Date:  2020

6.  MicroRNA‑15a‑5p‑targeting oncogene YAP1 inhibits cell viability and induces cell apoptosis in cervical cancer cells.

Authors:  Xu Chen; Ruiqin Cao; Haifang Liu; Tuanying Zhang; Xinrong Yuan; Shuxiang Xu
Journal:  Int J Mol Med       Date:  2020-08-12       Impact factor: 4.101

7.  miRNA-641 inhibits the proliferation, migration, and invasion and induces apoptosis of cervical cancer cells by directly targeting ZEB1.

Authors:  Rui Yao; Huzhong Zheng; Liqun Wu; Pingsheng Cai
Journal:  Onco Targets Ther       Date:  2018-12-11       Impact factor: 4.147

8.  DANCR-mediated microRNA-665 regulates proliferation and metastasis of cervical cancer through the ERK/SMAD pathway.

Authors:  Liyan Cao; Haihong Jin; Yue Zheng; Yu Mao; Zhanzhao Fu; Xin Li; Lixin Dong
Journal:  Cancer Sci       Date:  2019-01-19       Impact factor: 6.716

9.  miR-125a attenuates the malignant biological behaviors of cervical squamous cell carcinoma cells through Rad51.

Authors:  Zeping Liu; Jinchang Huang; Qiuju Jiang; Xiaoling Li; Xiaohui Tang; Shasha Chen; Liling Jiang; Genghua Fu; Sijun Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

10.  Long Noncoding RNA FOXD2-AS1 Promotes the Malignancy of Cervical Cancer by Sponging MicroRNA-760 and Upregulating Hepatoma-Derived Growth Factor.

Authors:  Xiaoqing Dou; Qun Zhou; Mingxiao Wen; Jiangyan Xu; Yingping Zhu; Shuzhen Zhang; Xianli Xu
Journal:  Front Pharmacol       Date:  2020-01-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.